Immunic AG

General information
Immunic AG
Am Klopferspitz 19
82152 Martinsried, Bavaria
Germany

Contact person: Manfred Gröppel, Chief Operating Officer
Company main phone: +49 (89) 250079460
Company main fax:  +49 (89) 250079466
Website:  www.immunic.de
Source of foundation:Subsidiary
Name of foundation source:Immunic, Inc., USA
Corporate description / mission:
Immunic, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic AG, is based in Planegg-Martinsried, Germany, where the company’s research and development activities are conducted.
State of ownership: Subsidiary
Headquarters: No
Remarks on ownership / listings
Immunic, Inc. is headquartered in San Diego, California. Its subsidiary, Immunic AG, is based in Planegg-Martinsried, Germany.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Immunotherapy
  • Small molecules
  • Other
Primary therapeutic areas:
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the nervous system / neurology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • R&D
  • Subsidiary
Customer segments:
  • Hospitals
  • Large biotech & big pharma
Summary Products / Services / Technologies
Description of products:
IMU-838 program and IMU-366 program
X